The US plans to liberalize competition in the nephropathy treatment market, and the two major dialysis leaders, Davita and Fresenius Medical, rapidly weakened.

Zhitongcaijing · 3d ago
The US plans to liberalize competition in the nephropathy treatment market, and the two major dialysis leaders, Davita and Fresenius Medical, rapidly weakened.